Nuvation Bio stock kpis
Want to see NUVB full AI Analyst Report?
Revenue by Type
Nuvation Bio reported revenue by type of $44.95M in Q3 2026, up 41.9% from Q2 2026 and up 242.6% year over year. The highest value was $83.23M in Q1 2026.
Breaks down revenue into sources such as product sales, licensing, collaboration and milestone payments, and grants, highlighting whether income is recurring or one-time. For clinical-stage Nuvation Bio, which likely has limited commercial sales, this reveals reliance on partnerships and milestone receipts to fund R&D, the timing risks to cash flow and runway, and how close the company is to generating steady product revenue.
Product revenue has moved from essentially zero to the company’s primary, steadily growing income stream over the past year—a direct reflection of IBTROZI’s commercial momentum (first‑line uptake, patient stacking and durable benefit). Collaboration/license income remains lumpy and milestone-driven, so overall top‑line stability now depends more on sustained product penetration than one‑off deals. That reduces reliance on episodic license spikes but elevates sensitivity to gross‑to‑net pressures, high SG&A/R&D spend and payer/testing dynamics; recent financing improves runway but introduces dilution tradeoffs.
NUVB Revenue by Type
| Period | Product | Collaboration & License Agreements | Total |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $27.46M | $17.49M | $44.95M |
| Q2 2026Jun 30, 2026 | $23.19M | $8.49M | $31.69M |
| Q1 2026Mar 31, 2026 | $18.51M | $64.72M | $83.23M |
| Q4 2025Dec 31, 2025 | $15.70M | $26.16M | $41.87M |
| Q3 2025Sep 30, 2025 | $7.72M | $5.40M | $13.12M |
| Q2 2025Jun 30, 2025 | $1.24M | $3.60M | $4.83M |
| Q1 2025Mar 31, 2025 | $0.00 | $3.08M | $3.08M |
| Q4 2024Dec 31, 2024 | $0.00 | $5.71M | $5.71M |
| Q3 2024Sep 30, 2024 | $0.00 | $727.00K | $727.00K |
| Q2 2024Jun 30, 2024 | $0.00 | $1.44M | $1.44M |
| Q1 2024Mar 31, 2024 | $0.00 | $0.00 | $0.00 |

